459 related articles for article (PubMed ID: 12825134)
1. Bezafibrate treatment: a new medical approach for PBC patients?
Kanda T; Yokosuka O; Imazeki F; Saisho H
J Gastroenterol; 2003; 38(6):573-8. PubMed ID: 12825134
[TBL] [Abstract][Full Text] [Related]
2. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.
Hazzan R; Tur-Kaspa R
J Clin Gastroenterol; 2010; 44(5):371-3. PubMed ID: 19881358
[TBL] [Abstract][Full Text] [Related]
3. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid.
Takeuchi Y; Ikeda F; Fujioka S; Takaki T; Osawa T; Yasunaka T; Miyake Y; Takaki A; Iwasaki Y; Kobashi H; Yamamoto K; Itoshima T
J Gastroenterol Hepatol; 2011 Sep; 26(9):1395-401. PubMed ID: 21443659
[TBL] [Abstract][Full Text] [Related]
4. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study.
Nakai S; Masaki T; Kurokohchi K; Deguchi A; Nishioka M
Am J Gastroenterol; 2000 Jan; 95(1):326-7. PubMed ID: 10638623
[No Abstract] [Full Text] [Related]
6. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis.
Matsuzaki Y; Tanaka N; Osuga T; Aikawa T; Shoda J; Doi M; Nakano M
Am J Gastroenterol; 1990 Jan; 85(1):15-23. PubMed ID: 1967512
[TBL] [Abstract][Full Text] [Related]
7. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R
Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of combined administration of ursodeoxycholic acid and hepthral in the treatment of primary biliary cirrhosis].
Avezov SA; Mansurov FKh
Klin Med (Mosk); 2004; 82(3):55-8. PubMed ID: 15114777
[TBL] [Abstract][Full Text] [Related]
9. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
Reig A; Sesé P; Parés A
Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
Dohmen K; Tanaka H; Haruno M
Fukuoka Igaku Zasshi; 2013 Oct; 104(10):350-61. PubMed ID: 24511666
[TBL] [Abstract][Full Text] [Related]
12. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis.
Akbar SM; Furukawa S; Nakanishi S; Abe M; Horiike N; Onji M
J Gastroenterol; 2005 Feb; 40(2):157-63. PubMed ID: 15770399
[TBL] [Abstract][Full Text] [Related]
14. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
Angulo P; Jorgensen RA; Keach JC; Dickson ER; Smith C; Lindor KD
Hepatology; 2000 Feb; 31(2):318-23. PubMed ID: 10655252
[TBL] [Abstract][Full Text] [Related]
15. A novel treatment for refractory primary biliary cirrhosis?
Miyaguchi S; Ebinuma H; Imaeda H; Nitta Y; Watanabe T; Saito H; Ishii H
Hepatogastroenterology; 2000; 47(36):1518-21. PubMed ID: 11148991
[TBL] [Abstract][Full Text] [Related]
16. Additional fibrate treatment in UDCA-refractory PBC patients.
Chung SW; Lee JH; Kim MA; Leem G; Kim SW; Chang Y; Lee HY; Yoon JS; Park JY; Lee YB; Cho EJ; Yu SJ; Kim YJ; Yoon JH
Liver Int; 2019 Sep; 39(9):1776-1785. PubMed ID: 31162879
[TBL] [Abstract][Full Text] [Related]
17. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.
Hosonuma K; Sato K; Yamazaki Y; Yanagisawa M; Hashizume H; Horiguchi N; Kakizaki S; Kusano M; Yamada M
Am J Gastroenterol; 2015 Mar; 110(3):423-31. PubMed ID: 25732417
[TBL] [Abstract][Full Text] [Related]
18. Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile?
Angulo P; Jorgensen RA; Lindor KD
Am J Gastroenterol; 2001 Nov; 96(11):3152-7. PubMed ID: 11721764
[TBL] [Abstract][Full Text] [Related]
19. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
Angulo P; Patel T; Jorgensen RA; Therneau TM; Lindor KD
Hepatology; 2000 Nov; 32(5):897-900. PubMed ID: 11050036
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.
Poupon RE; Huet PM; Poupon R; Bonnand AM; Nhieu JT; Zafrani ES
Hepatology; 1996 Nov; 24(5):1098-103. PubMed ID: 8903382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
